Promising drug for kids with rare muscle disease moves to next phase

NCT ID NCT06055959

Recruiting now Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This study is testing a drug called zilucoplan in children aged 2 to 17 with generalized myasthenia gravis, a disease that causes muscle weakness. The goal is to see how the drug works in the body, if it is safe, and if it helps control the disease. Only 8 children will take part, and they will receive the drug without a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS

Contacts and locations

Locations

Mg0014 20104
WITHDRAWN

Seoul, South Korea
Mg0014 20220
RECRUITING

Seoul, South Korea
Mg0014 40144
RECRUITING

Milan, Italy
Mg0014 40218
ACTIVE_NOT_RECRUITING

Warsaw, Poland
Mg0014 40735
RECRUITING

Glasgow, United Kingdom
Mg0014 40736
RECRUITING

London, United Kingdom
Mg0014 40774
RECRUITING

Katowice, Poland
Mg0014 50168
WITHDRAWN

Chicago, Illinois, 60611, United States
Mg0014 50574
WITHDRAWN

Flower Mound, Texas, 75028, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.